title: [Expression and its clinical significance of hsa-miR-155 in serum of endometrial cancer].
abstract: OBJECTIVE
  to investigate the expression of the hsa-miR-155 in serum of endometrial cancer and its clinical significance.
  
  
  METHODS
  collected 44 cases blood specimens before surgery operation from Sep. 2008 to Dec. 2009, and collected 12 cases blood specimens from the health of volunteers in comparison. Real time quantity PCR was used to detect the expression of hsa-miR-155 in those specimens and analyzed clinical pathological with the expression of hsa-mir-155 in endometrial cancer.
  
  
  RESULTS
  the expression of hsa-miR-155 was (3.9 ± 0.7) in endometrial cancer, which was significantly higher than that in control group (P < 0.01). The expressions of hsa-miR-155 were (3.7 ± 0.6), (3.9 ± 0.6) and (3.7 ± 0.6) times in well, moderately and poorly differentiated endometrial cancer, respectively, while there were not significant difference (P > 0.05). The expressions were (3.8 ± 0.6) and (3.9 ± 0.6) times between endometrioid adenocarcinoma and non-endometrioid adenocarcinoma, and there were significant difference (P > 0.05). The expressions were (2.1 ± 0.4) and (5.6 ± 0.8) times in stage I - II and III - IV endometrial cancer, respectively, in which there were significant difference (P < 0.05). The expressions of hsa-miR-155 were (5.5 ± 0.5) and (1.9 ± 0.2) times between lymph node metastasis and without lymph node metastasis in endometrial cancer, in which there were significant difference (P < 0.01).
  
  
  CONCLUSIONS
  Hsa-miR-155 may play an important role in the proliferation, and metastasis of endometrial cancer, which may be a indicator in the diagnosis and prognosis of endometrial cancer and may be used as a predictive biomarker.
authors.affiliation: Department of Obstetrics and Gynecology, the 169th Hospital of PLA, Hengyang of Hunan Province 421002, China.
authors.forename: Zhi-Qin
authors.initials: ZQ
authors.lastname: Tan
authors.forename: Fu-Xiang
authors.initials: FX
authors.lastname: Liu
authors.forename: Hai-Lin
authors.initials: HL
authors.lastname: Tang
authors.forename: Qi
authors.initials: Q
authors.lastname: Su
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000473:pathology; D000328:Adult; D014408:Biomarkers, Tumor / Q000097:blood / Q000235:genetics; D018269:Carcinoma, Endometrioid / Q000097:blood* / Q000473:pathology; D016022:Case-Control Studies; D016889:Endometrial Neoplasms / Q000097:blood* / Q000473:pathology; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008207:Lymphatic Metastasis; D035683:MicroRNAs / Q000097:blood* / Q000235:genetics; D008875:Middle Aged; D009367:Neoplasm Staging; D016133:Polymerase Chain Reaction / Q000379:methods; D011379:Prognosis
chemical_list: D014408:Biomarkers, Tumor; C524942:MIRN155 microRNA, human; D035683:MicroRNAs